RDD2024, held in Tucson one month ago, released its contents.
For those of you who could not attend, ask your colleagues to share the materials since it was an excellent RDD.
Many interesting updates, showing how intense the Inhalation Drug Delivery transition is between sustainability for pMDI gases and other issues and systemic delivery of drugs.
Some takeaways (with a bias on pMDIs, of course):
1) Focus on pMDI Gas Transition:
The conference saw a continued surge of interest in pMDI (pressurized metered dose inhalers) transitioning to propellants with low global warming potential (LGWP).
Kindeva Drug Delivery, with Nicholas Smalley and Ann Purrington, managed a best-ever regulatory session on how the regulatory challenges, with FDA's Bryan Newman and Markham Luke, MD PhD, and
Richard Lostritto, Ph.D. You should download the materials of those.
Regulatory presence is significant given the hurdles of this transition, which is easier than the CFC, but not that easy due to the gas characteristics, challenging valves, and formulations.
All the major players, including us - RxPack -and Università degli Studi di Parma, had posters about valves, formulations and measurement systems, and gas behaviors (Koura and Honeywell).
Kindeva Drug Delivery, Honeywell, and Bespak managed intriguing workshops.
2) Beyond Asthma and COPD:
The focus has broadened from traditional uses like asthma and COPD to other indications. Sessions covered inhaled delivery of large molecules for diseases like cystic fibrosis and pulmonary infections.
Talks explored using nanoparticles to deliver mRNA to the lungs for potential cancer treatments.
3) Nasal drug development sessions and posters addressed spray-drying nasal vaccines and methods for nasal-to-brain delivery.
Boehringer Ingelheim and the future of soft mist inhalers for delivery of systemic drugs APIs was an interesting angle, with Boehringer's cooperation with Kenox Pharmaceuticals, Inc. It is also clear that Boehringer Ingelheim's impetus on inhalation for COPD and Asthma is not what it used to be.
See you in Parma and Edinburgh in the next months.
#pmdi #inhalation #transition
Médico, padre. CMO and CCO HCM&C
1moMucha suerte por alli!